<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531737</url>
  </required_header>
  <id_info>
    <org_study_id>I14041/REFRACT</org_study_id>
    <nct_id>NCT02531737</nct_id>
  </id_info>
  <brief_title>Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer</brief_title>
  <acronym>REFRACT</acronym>
  <official_title>Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nintedanib (vargatef®) combined with&#xD;
      docetaxel are effective in second line of treatment in patients with no squamous non small&#xD;
      cell lung cancer refractory to first line chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      59 Patients with histologically documented stage IV NSCLC no squamous, after failure of first&#xD;
      line chemotherapy and refractory (progressive disease during first line chemotherapy), will&#xD;
      be enroled to receive docetaxel :75 mg/m² IV day 1 every 3 weeks with nintedanib&#xD;
      (vargatef®):200 mg X 2/day per os day2-day21.&#xD;
&#xD;
      Tumor response (according to RECIST) will be assessed via computed tomography or magnetic&#xD;
      resonance imaging scan every 6 weeks (evaluation of PFS) following completion of&#xD;
      chemotherapy.&#xD;
&#xD;
      Adverse events (AEs) were graded according to the National Cancer Institute Common Toxicity&#xD;
      Criteria, version 4.0&#xD;
&#xD;
      Quality of life(EQ5-D ) will be assessed every 6 weeks during chemotherapy. Tolerability will&#xD;
      be assessed at each visit based on Common Terminology Criteria for Adverse Events (CTCAE),&#xD;
      v4.0 criteria.&#xD;
&#xD;
      Total study duration per patient: approximately 12 months .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">September 26, 2020</completion_date>
  <primary_completion_date type="Actual">September 26, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median progression free survival</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>median progression free survival</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (NCIC-CTC version 4.0 criteria)</measure>
    <time_frame>Every 3 weeks during treatment up to 12 months from inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ5-D questionnaire)</measure>
    <time_frame>every 6 weeks up to 12 months from inlcusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>traitment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vargatef®</intervention_name>
    <description>Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle</description>
    <arm_group_label>traitment</arm_group_label>
    <other_name>Nintedanib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle</description>
    <arm_group_label>traitment</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed non-squamous NSCLC,&#xD;
&#xD;
          -  Metastatic NSCLC of stage IV (according to American Joint Committee on Cancers) or&#xD;
             recurrent NSCLC)&#xD;
&#xD;
          -  Patients without activating epidermal growth factor receptor (EGFR) mutation&#xD;
&#xD;
          -  Patients without anaplastic lymphoma kinase (ALK) rearrangement&#xD;
&#xD;
          -  Patients must have measurable lesion by RECIST 1.1&#xD;
&#xD;
          -  Refractory disease defined by documented progression during the first-line&#xD;
             chemotherapy based on a platinum doublet and third-generation drug (four or less&#xD;
             cycles) according to RECIST V.1.1&#xD;
&#xD;
          -  Age ≥18 years and &lt; 75 years&#xD;
&#xD;
          -  Performance status (PS) 0-1&#xD;
&#xD;
          -  Life expectancy of more than 12 weeks.&#xD;
&#xD;
          -  No history of other malignancy within the last 5 years, except for adequately treated&#xD;
             carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin.&#xD;
&#xD;
          -  Adequate organ function, evidenced by the following laboratory results within 3 weeks&#xD;
             prior to randomization: Normal hepatic function: bilirubin &lt; 1.5 x N, ALT (alanine&#xD;
             transaminase) and AST (aspartate aminotransferase ) &lt; 2.5 x N or &lt;5 x N in case of&#xD;
             liver metastasis&#xD;
&#xD;
          -  Normal renal function (calculated creatinine clearance ≥ 45 mL/min).&#xD;
&#xD;
          -  Normal Calcemia&#xD;
&#xD;
          -  Normal haematological function (polynuclear neutrophils &gt; 1.5 G/l, platelets &gt; 100&#xD;
             G/l).&#xD;
&#xD;
          -  Anticoagulation with a vitamin K antagonist and low-molecular-weight heparin (LMWH) is&#xD;
             authorized.&#xD;
&#xD;
          -  Antiplatelet treatment (aspirin authorized if &lt; 325 mg/d)&#xD;
&#xD;
          -  Treatment with dipyridamole, ticlopidine, clopidogrel is not authorized&#xD;
&#xD;
          -  Women of child bearing potential must use double effective contraception.&#xD;
&#xD;
          -  Men might be surgically sterile or accept to use an effective contraceptive procedure&#xD;
             during and until 6 months after the treatment.&#xD;
&#xD;
          -  Written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the trial drugs (nintedanib (vargatef®), docetaxel), peanut,&#xD;
             soya, to their excipients&#xD;
&#xD;
          -  Controlled disease after first line treatment&#xD;
&#xD;
          -  Contra indication to the use of the backbone treatment&#xD;
&#xD;
          -  Patients who were withdrawn from first line treatment due to toxicity without&#xD;
             documented disease progression or who received placebo (in the context of a clinical&#xD;
             trial) as prior treatment are not eligible.&#xD;
&#xD;
          -  Previous treatment with docetaxel&#xD;
&#xD;
          -  Small-cell lung cancer, bronchioloalveolar cancer, neuroendocrine cancer.&#xD;
&#xD;
          -  Previous therapy with vascular endothelial growth factor (VEGF) inhibitors except&#xD;
             bevacizumab&#xD;
&#xD;
          -  Centrally located tumour with radiographic evidence of local invasion of local blood&#xD;
             vessels&#xD;
&#xD;
          -  Radiographic evidence of cavitary or necrotic tumours at screening&#xD;
&#xD;
          -  Chemo-, hormone-, radio-(except for brain and extremities) or immunotherapy or therapy&#xD;
             with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks&#xD;
             prior to treatment with the trial drug.&#xD;
&#xD;
          -  Toxicity non resolute due to prior treatment &gt; grade I (except alopecia).&#xD;
&#xD;
          -  Radiotherapy (except extremities) within the past 3 months prior to baseline imaging&#xD;
&#xD;
          -  Persistence of clinically relevant therapy related toxicity from previous radiotherapy&#xD;
&#xD;
          -  Active brain metastases (e.g. stable for &lt;4 weeks, no adequate previous treatment with&#xD;
             radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone&#xD;
             therapy will be allowed if administered as stable dose for at least one month before&#xD;
             inclusion).&#xD;
&#xD;
          -  Uncontrolled arterial hypertension.&#xD;
&#xD;
          -  Concurrent radiotherapy, except for palliative bone irradiation.&#xD;
&#xD;
          -  Other concurrent severe illnesses (congestive heart failure, unstable angina,&#xD;
             significant arrhythmia or myocardial infarction less than 12 months before study&#xD;
             entry).&#xD;
&#xD;
          -  Stroke less than 6 months before study entry.&#xD;
&#xD;
          -  Psychiatric or neurological disorders preventing the patient from understanding the&#xD;
             nature of the trial&#xD;
&#xD;
          -  Grade &gt;=1 peripheral neuropathy&#xD;
&#xD;
          -  Uncontrolled infection.&#xD;
&#xD;
          -  Caval syndrome&#xD;
&#xD;
          -  Other organic disorders preventing inclusion in the trial&#xD;
&#xD;
          -  Malabsorption syndrome&#xD;
&#xD;
          -  Pregnancy and breast-feeding&#xD;
&#xD;
          -  Surgery less than two months before study entry.&#xD;
&#xD;
          -  Follow-up not feasible.&#xD;
&#xD;
          -  Incarcerated and institutionalized&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Vergnenegre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU LImoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Gap</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Sud</name>
      <address>
        <city>LOrient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier F. Quesnay</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instiut de Cancérologie</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Villefranche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

